Skip to main content
OpenTrials
Completed

NCT Number: NCT04463875

Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention, by an observational, prospective real-world study in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3).

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Corfu HC

Corfu, 49100, Greece

About this study

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention.

An observational, prospective real-world study. After a one-month baseline period, Vivinor® was introduced in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3). Secondary endpoints included changes in mean intensity of migraine and in days with use of acute migraine medications. Changes in scores of Migraine Disability Assessment questionnaire (MIDAS), Headache Impact Test-6 (HIT-6), Migraine Therapy Assessment questionnaire (MTAQ), MSQ-QOL (Migraine-Specific Quality of life questionnaire), HADS (Hospital Anxiety and Depression Scale) were also evaluated. Those with ≥50% reduction in monthly migraine days during T3 compared to BL were considered Vivinor®-responders.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • established diagnosis of episodic migraine with or without aura for more than one year prior to study entry
  • evidence of 4-14 migraine days per month during the last trimester prior to screening
  • participants may had been either treatment- naive or not suitable for or had failed previous migraine pharmacological prophylactic treatments
  • were able to fully understand protocol and study information provided by the investigators.
  • enrolled patients should take no other preventive treatment or use any other migraine prophylactic method during the three months before entering the study and throughout the study period.

Exclusion criteria

  • older than 50 years of age at migraine onset
  • evidence of MOH
  • pregnant or nursing females
  • history of tension-type, cluster or hemiplegic headache
  • history of severe anaphylactic reactions to any of the intervention's ingredients
  • evidence of severe systemic diseases
  • history or evidence of major psychiatric disorder.

Treatment and study plan

magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10

Dietary Supplement

Supplementation per os

Other names: Vivinor

Primary outcomes

  1. Change in monthly migraine days

    Time frame: 3 months

    Change in monthly migraine days between baseline period (BL) and the third month of treatment (T3)

Secondary outcomes

  1. Mean intensity of migraine

    Time frame: 3 months

    Changes in mean intensity of migraine between baseline period (BL) and the third month of treatment (T3)

  2. days with use of acute migraine medications

    Time frame: 3 months

    Changes in days with use of acute migraine medications between baseline period (BL) and the third month of treatment (T3)

  3. Migraine Disability Assessment questionnaire (MIDAS)

    Time frame: 3 months

    Changes in scores of Migraine Disability Assessment questionnaire (MIDAS) during T3

  4. Headache Impact Test-6 (HIT-6)

    Time frame: 3 months

    Changes in Headache Impact Test-6 (HIT-6) during T3

  5. Migraine Therapy Assessment questionnaire (MTAQ)

    Time frame: 3 months

    Changes in Migraine Therapy Assessment questionnaire (MTAQ) during T3

Other outcomes

  1. Migraine responders

    Time frame: 3 months

    Those with ≥50% reduction in monthly migraine days during T3 compared to BL were considered Vivinor®-responders.

Sponsors and collaborators

Lead sponsor

Corfu Headache Clinic

Other

Registry information

Official study title

Real World, Open Label Prospective Experience of Supplementation With a Fixed Combination of Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Jul 9, 2020
Registry last updated
Jul 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.